Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
the purpose of this study is to describe the way Faslodex is used in France, in patients suffering from initial breast cancer, that is to evaluate Faslodex treatment duration and to determine patients profile
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Patients suffering from initial breast cancer, treated with Faslodex, treatment which was stopped during 2007 |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Evaluate Faslodex therapeutic strategy and treatment duration | At the end of the study | |
| Describe the characteristics of patients treated with Faslodex | At the end of the study |
Not provided
Not provided
Inclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Hospital sample
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Alain FLINOIS | TNS Healthcare - France138, avenue Marx Dormoy92120 Montrouge | Principal Investigator |
Not provided
Not provided
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| D017437 |
| Skin and Connective Tissue Diseases |